{
    "id": 503,
    "fullName": "GNAQ Q209P",
    "impact": "missense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "GNAQ Q209P lies within the G-alpha domain of the Gnaq protein (UniProt.org). Q209P results in similar effects on cell proliferation and apoptosis as wild-type Gnaq in culture (PMID: 23904987), however, results in increased Erk phosphorylation (PMID: 23904987, PMID: 30352874), decreased binding to effector proteins, G-protein beta gamma, and signaling proteins, and diminished GTPase activity (PMID: 30352874), and therefore, is predicted to result in a loss of Gnaq protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17968,
                    "pubMedId": 30352874,
                    "title": "Atypical activation of the G protein G\u03b1q by the oncogenic mutation Q209P.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352874"
                },
                {
                    "id": 8772,
                    "pubMedId": 23904987,
                    "title": "GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23904987"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2776,
        "geneSymbol": "GNAQ",
        "terms": [
            "GNAQ",
            "CMC1",
            "G-ALPHA-q",
            "GAQ",
            "SWS"
        ]
    },
    "variant": "Q209P",
    "createDate": "05/12/2014",
    "updateDate": "03/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 101966,
        "transcript": "NM_002072",
        "gDna": "chr9:g.77794572T>G",
        "cDna": "c.626A>C",
        "protein": "p.Q209P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16782,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FR900359 inhibited ERK activation and proliferation, and induced cell-cycle arrest, apoptosis and differentiation in a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 30567972).",
            "molecularProfile": {
                "id": 560,
                "profileName": "GNAQ Q209P"
            },
            "therapy": {
                "id": 8196,
                "therapyName": "FR900359",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14908,
                    "pubMedId": 30567972,
                    "title": "Effects of Oncogenic G\u03b1q and G\u03b111 Inhibition by FR900359 in Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30567972"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22253748).",
            "molecularProfile": {
                "id": 560,
                "profileName": "GNAQ Q209P"
            },
            "therapy": {
                "id": 1682,
                "therapyName": "Enzastaurin",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 982,
                    "pubMedId": 22253748,
                    "title": "The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22253748"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10595,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sotrastaurin (AEB071) induced cell-cycle arrest and apoptosis, and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22653968).",
            "molecularProfile": {
                "id": 560,
                "profileName": "GNAQ Q209P"
            },
            "therapy": {
                "id": 621,
                "therapyName": "AEB071",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8663,
                    "pubMedId": 22653968,
                    "title": "Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-\u03baB pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22653968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNAQ Q209P in culture (PMID: 22515704).",
            "molecularProfile": {
                "id": 560,
                "profileName": "GNAQ Q209P"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8672,
                    "pubMedId": 22515704,
                    "title": "Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22515704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209P in culture (PMID: 22550165).",
            "molecularProfile": {
                "id": 560,
                "profileName": "GNAQ Q209P"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8677,
                    "pubMedId": 22550165,
                    "title": "Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22550165"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 560,
            "profileName": "GNAQ Q209P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 101966,
            "transcript": "NM_002072",
            "gDna": "chr9:g.77794572T>G",
            "cDna": "c.626A>C",
            "protein": "p.Q209P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}